Industry
CLUSTER aims to develop strategic relationships with key industry partners. CLUSTER will strengthen our position as global leaders of JIA stratified medicine, leveraging expertise of the acknowledged leaders and maximising synergies between basic science, world-class data analytics and biostatistics, and trials expertise through integration with industry, patient and clinician partnerships.
How will Industry work with the CLUSTER Consortium
Engagement with the CLUSTER Consortium is acknowledged as a major opportunity by Industry partners, providing rapid access to large JIA cohorts, cross-platform omics and biological data which will illuminate treatment biomarkers and new therapeutic targets, and to our UK-wide network of centres for clinical trials, with paediatric NIHR-BRC and CRF facilities.
It is key to develop strategic relationships with key industry partners.
Drug Development Infographic
The CLUSTER Champions worked with the CLUSTER Industry Committee and CLUSTER Researchers to develop an infographic which describes the journey of drug development. We hope that this will be helpful to anyone interested in the process, and potential challenges, involved in the development of a new medicine or therapy.
Industry Partners
AbbVie
We are a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company. AbbVie has been striving to advance the standard of care in rheumatology for over 20 years. We are committed to creating a better tomorrow for patients everywhere.
As part of our commitment to patients with rheumatic diseases, we have partnered with academia and consortia to fuel scientific progress and ultimately to benefit patients. Childhood onset immune-mediated arthritides known collectively as Juvenile idiopathic arthritis (JIA) present significant challenges for patients and their families and can lead to disability at a young age. Early diagnosis and individualized treatment are important unmet needs for patients living with JIA. AbbVie is honoured to be a partner in the CLUSTER Consortium, sharing our expertise in Precision Medicine with academic and industry partners to improve the lives of JIA patients through the identification of distinct biomarkers of childhood arthritis that reflect treatment response and disease course.
Eli Lilly
Lilly is a medicine company turning science into therapies to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are advancing new discoveries to address some of the world’s most significant health challenges: redefining diabetes and obesity care; advancing the fight against Alzheimer’s disease; providing options for debilitating immune system disorders; and transforming the management of difficult-to-treat cancers. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
GlaxoSmithKline
GlaxoSmithKline plc is a British pharmaceutical company.
Pfizer
Pfizer: Breakthroughs that change patient’s lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines.
Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.
Rheumatic diseases in children and adolescents can have a profound impact on a person’s quality of life, causing pain and limiting daily function. Despite the availability of multiple treatments, many patients do not reach remission and need more options to improve outcomes. Building on pioneering science, we are relentlessly pursuing next-generation therapies and exploring new approaches and pathways with the goal of delivering superior outcomes. Pfizer are proud to be part of CLUSTER.
Sobi
Swedish Orphan Biovitrum AB (Sobi) is an international biopharmaceutical company based in Sweden.
Sobi care about rare disease patients. Sobi is dedicated to develop and deliver innovative therapies to improve the lives of rare disease patients. Within the therapeutic area of immunology, Sobi is dedicated to the treatment of rare, ultra-rare and severe autoinflammatory and autoimmune diseases.
UCB
UCB is a global biopharmaceutical company dedicated to transforming the lives of people with immunological and neurological conditions.
We are a proud partner of the CLUSTER Consortium, working towards a deeper understanding of JIA and JIA-uveitis mechanisms and pathways, to aid personalised treatment approaches and discover novel therapeutic targets, with the goal to improve patient outcomes.
Our commitment aligns with the Consortium aims of developing personalised medicines for those young patients through deep understanding of disease.
UCB’s expertise in innovative antibody discovery platforms positions us as an ideal CLUSTER partner for developing novel antibody tools and therapeutics.
UK Research & Innovation MRC Information
For more information, see the UKRI MRC website using the following links:
FAQ
Q1: Who Do I Contact About Research Opportunities and Collaborations?
For collaboration please contact the CLUSTER Research Manager, Zoe Wanstall, at clusterconsortium@ucl.ac.uk
Mailing List Sign Up
Join the CLUSTER Mailing List
Joining the CLUSTER mailing list is best way to stay informed about everything we are doing, the latest research findings, news and events and Industry partnerships.
We won't bombard you, and we will protect your data and privacy.